

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1681)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Consun Pharmaceutical Group Limited (the “**Company**”) dated 24 April 2017 (the “**Announcement**”) relating to completion of the Share Buy-back. Terms used in this announcement shall have the same meaning as those defined in the Announcement unless the context requires otherwise.

The board of directors of the Company would like to clarify that due to clerical error, note 1(iii) of the Announcement shall read “110,050,000 Shares are held by Guido Limited, a company directly owned by Mr. Young Wai Po Peter” instead of “11,050,000 Shares are held by Guido Limited, a company directly owned by Mr. Young Wai Po Peter” on page 2 of the Announcement.

Save for the aforesaid, the contents of the Announcement remain the same.

By Order of the Board
Consun Pharmaceutical Group Limited
An Yubao
Chairman

Hong Kong, 25 April 2017

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong and Mr. LIN Sheng as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.